Puerto Rico Healthcare Daily
SEE OTHER BRANDS

Exploring the health and wellness news of Puerto Rico

Puerto Rico Healthcare Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Puerto Rico Healthcare Daily.

Press releases published on May 28, 2025

Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference

Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference

BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during the Noble Capital Markets’ 2025 Emerging Growth Virtual Equity …

Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

NEW YORK and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment …

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” OR “Vaxart”) today answers additional …

Yerbaé Joins TikTok Shop to Accelerate Growth and Expand Digital Reach

Yerbaé Joins TikTok Shop to Accelerate Growth and Expand Digital Reach

SCOTTSDALE, Ariz., May 28, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, announces its acquisition partner, Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) …

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of …

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will …

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a …

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that …

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President …

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today …

R1 Announces Investment from Khosla Ventures as it Accelerates AI-Driven Healthcare Transformation

R1 Announces Investment from Khosla Ventures as it Accelerates AI-Driven Healthcare Transformation

MURRAY, Utah, May 28, 2025 (GLOBE NEWSWIRE) -- R1, an industry leader in managing and intelligently automating healthcare revenue management with over 20 years of experience, today announced an investment from Khosla Ventures, a leading backer of …

Saudi Arabia to Showcase Ambitious Biotech Agenda at BIO 2025

Saudi Arabia to Showcase Ambitious Biotech Agenda at BIO 2025

RIYADH, Kingdom of Saudi Arabia, May 28, 2025 (GLOBE NEWSWIRE) -- Saudi Arabia is set to make a high-impact appearance at BIO International Convention 2025, June 16-19, 2025 at the Boston Convention and Exhibition Center, where it will host a national …

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

PURCHASE, N.Y., May 28, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its tenth Conversations video …

MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan

MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today issued a Letter to Shareholders from the Company’s Board of Directors ( …

Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production

Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production

ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental …

Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors

Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors

LONDON and PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the …

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that its management team is scheduled …

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, …

BioStem Announces Notice of Allowance for Three New U.S. Patent Applications

BioStem Announces Notice of Allowance for Three New U.S. Patent Applications

POMPANO BEACH, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc.  (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that …

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service